First CAR-T Therapy for Solid Tumors Approved by JICC for Global Patients

Revolutionizing Cancer Treatment with CAR-T Therapy

The Jiahui International Cancer Center (JICC) has made headlines after receiving approval for Satri-cel (CT041, Kaileimei®), the world’s first CAR-T therapy targeting solid tumors. This significant milestone not only enhances oncology care but also offers hope to patients around the globe battling advanced gastric cancer, specifically adenocarcinoma. The therapy is designed for individuals who are positive for Claudin 18.2 and negative for HER2, and who have failed at least two previous lines of treatment.

A New Hope for Cancer Patients

Approved by the National Medical Products Administration of China (NMPA), this innovative treatment is set to change the landscape of cancer therapy. The introduction of Satri-cel marks a pivotal moment in oncology, as CAR-T therapies have primarily been restricted to hematological malignancies.

Dr. Linli Xuan, Chief of Medical Oncology at JICC, expressed her enthusiasm, noting that the success of CAR-T therapies in treating solid tumors has been an ongoing challenge in the field of oncology. She emphasized how this advancement not only brings renewed hope for advanced gastric cancer patients but also underlines China's growing influence in developing transformative cancer treatments.

Global Access to Advanced Cancer Treatments

JICC is strategically positioned as one of China’s leading centers for advanced cancer care, working to ensure both local and international patients gain access to this groundbreaking therapy. The center’s multidisciplinary cancer program offers specialized services geared toward international patients, demonstrating its commitment to facilitating access to cutting-edge oncology innovations.

In recent years, JICC has treated patients from diverse backgrounds, showcasing the international appeal of innovative cancer therapies available in China. The urgency for global access to novel cancer treatments initiated from China’s rapidly evolving medical landscape is anticipated to increase following the approval of the first CAR-T therapy for solid tumors.

Comprehensive Cancer Care and Support

The services provided by JICC are not limited to CAR-T therapy. They encompass a full range of oncology services, including medical oncology, surgical oncology, radiation therapy, precision medicine, and advanced cellular therapies. JICC’s multi-specialty consultations, multilingual support, and refined care protocols re-emphasize the center's dedication to connecting patients worldwide to the latest in cancer treatment advancements.

Through a personalized treatment planning process and dedicated international support services, JICC differentiates itself by providing tailored care for each patient seeking innovative solutions for cancer treatment. The center’s approach combines expert consultations with state-of-the-art treatment options, reinforcing its reputation as a global leader in oncology.

As the medical community and patients alike celebrate this historic accomplishment, the expectation remains—this is just the beginning of CAR-T therapies for solid tumors, with additional advancements on the horizon, paving the way for further innovations in cancer treatment.

For international patient inquiries, please contact JICC via email at [email protected] or reach out through WhatsApp at +852 4619 1904.